Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue 6, 2008, Pages 333-340

  Schurman, L ^a   McCarthy, A D ^b   Sedlinsky, C ^a   Gangoiti, M V ^b   Arnol, V ^b   Bruzzone, L ^b   Cortizo, A M ^b,c  

^a HOSPITAL FRANCÉS   (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c FACULTAD DE CIENCIAS EXACTAS   (Argentina)

Author keywords

Advanced glycation end product; Metformin; Osteoblasts; Oxidative stress; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALKALINE PHOSPHATASE; CASPASE 3; METFORMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; ENZYME ACTIVITY; NONHUMAN; OSTEOBLAST; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; GLYCOSYLATION END PRODUCTS, ADVANCED; KINETICS; METFORMIN; OSTEOBLASTS; OSTEOSARCOMA; RATS; SERUM ALBUMIN, BOVINE;

EID: 46749116766     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-992786     Document Type: Article

References (43)

1. Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L, Graves DT. Advanced glycation end products stimulate osteoblast apoptosis via MAP kinase and cytosolic apoptotic pathways. Bone 2006; 40 (2): 345-353
2. Al-Mashat HA, Kandru S, Liu R, Behl Y, Desta T, Graves DT. Diabetes enhances mRNA levels of proapoptotic genes and caspase activity which contribute to impaired healing. Diabetes 2006; 55: 487-495
3. Bellin C, Wiza DH de, Wiernsperger NF, Rosen P. Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin. Horm Metab Res 2006; 38: 732-739
4. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP. Understanding RAGE, the receptor for Advanced Glycation End Products. J Mol Med 2005; 83: 876-886
5. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation - a new therapeutic target? Curr Opin Invest Drugs 2006; 74: 985-991
6. Bouillon R. Diabetic bone disease. Calcif Tissue lnt 1991; 49: 155-160
7. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
8. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625
9. Carnevale V, Romagnoli E, D'Erasmo E. Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 2004; 20: 196-204
10. Cortizo AM, Etcheverry SB. Vanadium derivatives act as growth factor-mimetic compounds upon differentiation and proliferation of osteoblast-like UMR106 cells. Mol Cell Biochem 1995; 145: 97-102
11. Cortizo AM, Lettieri MG, Barrio DA, Mercer N, Etcheverry SB, McCarthy AD. Advanced glycation endproducts (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem 2003; 250: 1-10
12. Cortizo AM, Sedlinsky C, McCarthy AD, Blanco A, Schurman L. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 2006; 536: 38-46
13. Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: Where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007; 115: 69-84
14. Haslbeck K-M, Schleicher E, Bierhaus A, Nawroth P, Haslbeck M, Neundörfer B, Heuss D. The AGE/RAGE/NF-kB pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005; 113: 288-291
15. Hein G, Weiss C, Lehmann G, Niwa T, Stein G, Franke S. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis 2006; 65: 101-104
16. Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxford) 2003; 42: 1242-1246
17. Kaji Y, Amano S, Usui T, Oshika T, Yamashiro K, Ishida S, Suzuki K, Tanaka S, Adamis AP, Nagai R, Horiuchi S. Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci 2003; 44: 521-528
18. Krakauer JC, MacKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes mellitus. Diabetes 1995; 44: 775-782
19. Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M, Nagata K. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005; 20: 1647-1658
20. Laemmli UK. Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
21. Lowry OH, Rosebrough NJ, Farr AJ, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-275
22. Marx N, Watcher D, Ivanova N, Rautzenberg K, Jung A, Friedl R, Hombach V, Caterina R de, Basta G, Wautiers JL. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004; 53: 2662-2668
23. McCarthy AD, Etcheverry SB, Bruzzone L, Cortizo AM. Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells. Mol Cell Biochem 1997; 170: 43-51
24. McCarthy AD, Etcheverry SB, Bruzzone L, Lettieri G, Barrio DA, Cortizo AM. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol 2001; 2: 16
25. McCarthy AD, Etcheverry SB, Cortizo AM. Advanced glycation end-product-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation. Acta Diabetol 1999; 36: 45-52
26. Mercer N, Ahmed H, Etcheverry SB, Vasta GR, Cortizo AM. Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells. Mol Cell Biochem 2007, DOI 10.1007/s11010-007-9557-8
27. Mercer N, Ahmed H, McCarthy AD, Etcheverry SB, Vasta GR, Cortizo AM. AGE-R3/galectin-3 expression in osteoblast-like cells: regulation by AGEs. Mol Cell Biochem 2004; 266: 17-24
28. Molinuevo MS, Barrio DA, Cortizo AM, Etcheverry SB. Antitumoral properties of two new vanadyl(IV) complexes on osteoblasts in culture. Role of apoptosis and oxidative stress. Cancer Chemother Pharmacol 2004; 53: 163-172
29. Mukherjee TK, Mukhopadhyay S, Hoidal JR. The role of reactive oxygen species in TNFalpha-dependent expression of the receptor for advanced glycation end products in human umbilical vein endothelial cells. Biochim Biophys Acta 2005; 1744: 213-223
30. Odetti P, Monacelli F, Storace D, Robaudo C, Rossi S, Deferrari G, Barreca T. Correlation between pentosidine and endothelin-1 in subjects undergoing chronic hemodialysis. Horm Metab Res 2006; 38: 817-820
31. Ouslimani N, Mahrouf M, Peynet J, Bonnefont-Rousselot D, Cosson C, Legrand A, Beaudeux JL. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism 2007; 56: 308-313
32. Partridge NC, Alcorn D, Michelangeli VP, Ryan G, Martin TJ. Morphological and biochemical characterization of four clonal osteogenic sarcoma cell lines of rat origin. Cancer Res 1983; 43: 4308-4312
33. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 1363-1374
34. Quartes LD, Yahay DA, Lever LW, Caton R, Wenstrup RJ. Distinct proliferative and differentiated stages of murine MC3T3E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res 1992; 7: 683-692
35. Scharnagl H, Stojakovic T, Winkler K, Rosinger S, März W, Boehm BO. The HMG-CoA reductase inhibitor Cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2007; 115: 372-375
36. Schwartz AV. Diabetes Mellitus: Does it affect bone? Calcif Tissue Int 2003; 73: 515-519
37. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR. Older women with diabetes have an increased risk of fracture: A prospetive study. J Clin Endocrinol Metab 2001; 86: 32-38
38. Strotmeyer ES, Cauiey JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, Rekeneire N de, Harris TB, Newman AB. Non traumatic fracture risk with diabetes mellitus and impaired fasting glucose in oldet white and black adults: the health, aging and body composition study. Ann Intern Med 2005; 165: 1612-1617
39. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem 2000; 275: 25781-25790
40. UKPDS 34. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
41. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21
42. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteopor lnt 2007; 18: 427-444
43. Vestergaard P, Rejnmark L, Moselkide L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005; 48: 1292-1299